Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleosome assembly protein 1-like 4 pseudogene 3 (NAP1L4P3) is a human pseudogene, meaning it is a DNA sequence that closely resembles a functional gene (in this case, likely derived from the NAP1L4 gene) but is no longer capable of producing a functional protein product[2][4][6]. Pseudogenes are typically the result of gene duplication or retrotransposition followed by mutations that disable their function[4]. Although pseudogenes are considered nonfunctional "junk" DNA, some can play regulatory roles at the RNA level, for example by acting as decoys for microRNAs or being processed into small interfering RNAs (siRNAs) that regulate the expression of protein-coding genes[3][4]. However, there is no evidence that NAP1L4P3 functions as a therapeutic target, biomarker, or drug target, nor is there evidence directly implicating this pseudogene in specific disease processes or normal cellular functions[6][4]. As a pseudogene, it is not classified as a receptor, enzyme, transporter, or other conventional drug target class[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleosome assembly protein 1-like 4 pseudogene 3 (NAP1L4P3).